PDS Biotechnology Corp (PDSB) Earning Prediction
PDS Biotechnology Corp (PDSB) is set to release its earnings performance on 03/26 07:30:00 ET in Pre-Market trading. Consensus forecasts predict a revenue of - and an earnings per share (EPS) of -0.20 for the . With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
Earnings Surprise Analysis
PDSB Transcript
The earnings call reveals financial constraints, with a net loss and declining cash reserves, raising sustainability concerns. The VERSATILE-003 trial pause and lack of clarity on cost savings add uncertainty. The Q&A highlighted management's vague responses on key issues, such as trial adjustments and strategic interests, which may worry investors. Despite some positive developments in trials, market competition and reliance on external collaborations pose risks. Overall, these factors suggest a negative sentiment, likely resulting in a -2% to -8% stock price movement.
The earnings call summary presents a mixed picture: positive developments in clinical trials and collaborations, but financial challenges persist. The Q&A section highlights promising trial data and competitive positioning, yet management's vague responses and financial strain (net loss increase, cash balance decline) raise concerns. No new partnerships or major strategic shifts were announced, and the lack of guidance on key trials adds uncertainty. Considering these factors, the stock price is likely to remain stable, leading to a neutral prediction.
The earnings call summary highlights decreased losses and expenses, which is positive, but the Q&A reveals concerns about trial enrollment, lack of financial guidance, and competition. The financial health is fragile with a net loss and cash concerns. The debt refinancing offers short-term relief but adds obligations. The potential $11 million from warrants is uncertain. Overall, the company's financial and strategic outlook remains challenging, leading to a negative sentiment.
The earnings call presents a mixed outlook. Positive aspects include reduced net loss and operating expenses, and a promising clinical trial pipeline. However, financial risks, supply chain challenges, and competitive pressures persist. The Q&A session revealed management's lack of transparency regarding trial enrollment and financial guidance, raising concerns. Despite these issues, the company's strategic initiatives and debt refinancing provide some stability. Without a market cap, the stock's reaction is uncertain, leading to a neutral sentiment prediction for the next two weeks.
PDSB Report
Frequently Asked Questions
What is the PDS Biotechnology Corp {quarter} Earnings Release Date and Time?
PDS Biotechnology Corp (PDSB) is scheduled to release its {quarter} earnings report on Mar 26, 2026, Pre-Market (approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for PDS Biotechnology Corp {quarter} Revenue and EPS?
Analysts' consensus predicts {revenue} in revenue and an EPS of -0.20 for PDS Biotechnology Corp's {quarter}.
What Does Intellectia's AI Predict for PDS Biotechnology Corp {quarter} Earnings?
Intellectia's exclusive AI algorithms forecast a {conclusion} for PDS Biotechnology Corp's {quarter} earnings, with a prediction date of Mar 26, 2026. PDS Biotechnology Corp {summary}
How Can I Use This Earnings Prediction to Trade PDSB Stock?
Leverage Intellectia's AI forecast to position trades ahead of the Mar 26, 2026 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like PDS Biotechnology Corp {quarter}?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company's earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They're updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
